Evaluation of Exparel Adductor Canal Field Block for Pain Control After ACL Reconstruction
Status:
Recruiting
Trial end date:
2022-03-02
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized study for adult patients presenting to the Carilion Clinic
Institute of Orthopedics and Neurosurgery. Patients undergoing isolated ACL reconstruction
will be eligible for inclusion. All patients will receive an adductor canal block (either
with bupivacaine or Exparel. Patients will be given a pain diary for self-report of pill
counts, pain scores, block duration, and pain control satisfaction). Pill counts and pain
scores will also be taken by a team member at two and six-week post-operative visits. Primary
outcomes include opioid requirements and pain scores.